Journal article
Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy
M Crane, A Avihingsanon, R Rajasuriar, P Velayudham, D Iser, A Solomon, B Sebolao, A Tran, T Spelman, G Matthews, P Cameron, P Tangkijvanich, GJ Dore, K Ruxrungtham, SR Lewin
Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2014
Abstract
We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor α, and interferon γ (IFN-γ) were all associated with elevated liver enzyme levels..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medicine Research Council (NHMRC)
Awarded by American Foundation
Funding Acknowledgements
This work was supported by the National Health and Medicine Research Council (NHMRC APP1024066 to M. C., S. R. L., and G. M.) and the American Foundation for AIDS Research Mathilde Krim Fellowship for Basic Biomedical Research (award 107962-49-RKGN to M. C.).